诺华品牌怎么样 申请店铺

我要投票 诺华在化学药物行业中的票数:550 更新时间:2025-04-19
诺华是哪个国家的品牌?「诺华」是 北京诺华制药有限公司 旗下著名品牌。该品牌发源于瑞士,由创始人菲立普·雅克·路易·巴罗斯在1996年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力诺华品牌出海!通过在本页面挂载诺华品牌的产品链接和联系邮箱,可以提高诺华产品曝光!跨境电商爆单神器,目前只要100元/年哦~

诺华怎么样

1996年,瑞士莱茵河畔两家拥有百年历史的公司--汽巴-嘉基公司和山德士公司宣布合并,成立诺华公司。集团总部位于瑞士巴塞尔。截止2011年,诺华集团业务遍及全球140多个国家和地区,拥有124,000位全职员工;净销售额达586亿美元,名列制药行业全球第二(按2011年《制药经理人》公布的全球50强医药企业排名);核心研发支出约为96亿美元。诺华公司专注于医药保健领域,拥有:创新药品、眼科保健(爱尔康)、成本节约型非专利药品(山德士)、预防性疫苗及诊断器材、非处方药以及动物保健产品等多元化的六大业务组合。

诺华动物保健作为诺华集团的分支,研究、开发、生产并销售动物保健产品,是全球领先的动物保健品供应商,在全世界拥有5大研发基地和6个生产基地。我们的目的:挽救、延长并改善动物的生命。公司在动物疾病防治领域、抗寄生虫、抗感染、农场卫生和疫苗方面的创新满足了全世界兽医宠物主人和畜禽生产者们的需求。2011年,诺华动物保健的净销售额为13亿美金。

诺华动物保健(中国)是诺华在中国的独资企业,成立于1990年,注册资金3000万美元。公司的生产基地位于上海奉贤五四农场内, 拥有全套先进生产设备和设施。自建厂以来,公司不断完善质量体系,严格遵守中国兽药生产质量管理规范和瑞士总部的质量方针政策,成为第一家通过中国农业部兽药GMP认证的专业化兽药企业。目前公司的主要产品有枝原净®、康舒秘®、扶本康®、山字®、盈得静®、盈取静®、爱吉特®等。产品不仅畅销于中国国内的兽药市场,而且还出口东南亚、南美洲、澳洲等国家和地区。随着业务拓展需要,公司即将携系列优质宠物产品进入中国市场,敬请关注。

诺华动物保健(中国)致力于成为中国客户和员工心目中最为出色的动物保健公司,通过不断为客户提供创新的产品和领先服务促进中国畜牧业的健康发展。



In 1996, Ciba Cargill and Sandoz, two hundred year old companies on the Rhine River in Switzerland, announced a merger to establish Novartis. The group is headquartered in Basel, Switzerland. As of 2011, Novartis group has business in more than 140 countries and regions around the world, with 124000 full-time employees; its net sales reached US $58.6 billion, ranking the second in the world in the pharmaceutical industry (according to the ranking of the top 50 pharmaceutical enterprises published by the pharmaceutical manager in 2011); its core R & D expenditure is about US $9.6 billion. Novartis focuses on the field of medical and health care, with six diversified business combinations: innovative drugs, ophthalmic health care (Erkang), cost-saving generic drugs (Sandoz), preventive vaccines and diagnostic equipment, over-the-counter drugs and animal health products. As a branch of Novartis group, Novartis animal health research, development, production and sales of animal health products, is the world's leading supplier of animal health products, with 5 R & D bases and 6 production bases in the world. Our goal: to save, prolong and improve the lives of animals. The company's innovations in animal disease prevention and control, anti parasite, anti infection, farm sanitation and vaccine meet the needs of veterinary pet owners and livestock and poultry producers all over the world. In 2011, Novartis's net sales of animal health were $1.3 billion. Novartis animal health (China) is a wholly owned enterprise of Novartis in China, established in 1990 with a registered capital of US $30 million. The company's production base is located in Shanghai Fengxian 54 farm, with a full set of advanced production equipment and facilities. Since the establishment of the plant, the company has constantly improved its quality system, strictly abided by the quality management standards of China's veterinary drug production and the quality policies of the Swiss headquarters, becoming the first specialized veterinary drug enterprise that has passed the GMP certification of the Ministry of agriculture of China. At present, the company's main products include zhiyuanjing, kangshumi, fubenkang, Shanzi, yingdejing, yingzhujing, and iqit. The products not only sell well in China's domestic veterinary drug market, but also export to Southeast Asia, South America, Australia and other countries and regions. With the need of business development, the company will bring a series of high-quality pet products into the Chinese market, please pay attention. Novartis animal health (China) is committed to becoming the most outstanding animal health company in the eyes of Chinese customers and employees, and promoting the healthy development of China's animal husbandry by continuously providing customers with innovative products and leading services.

本文链接: https://brand.waitui.com/4b6ab5c3a.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

居然智家:推举董事、执行总裁王宁代为履行董事长等职责

36氪获悉,居然智家发布公告,鉴于公司董事长汪林朋暂无法履行董事长职责,董事会同意由董事、执行总裁王宁在此期间代为履行董事长、法定代表人、CEO、董事会战略和投资委员会主任委员、董事会预算委员会主任委员职责。

2小时前

海康威视:一季度净利润20.39亿元,同比增长6.41%

36氪获悉,海康威视披露一季报,公司2025年第一季度实现营业收入185.32亿元,同比增长4.01%;归属于上市公司股东的净利润20.39亿元,同比增长6.41%。

2小时前

海康威视:2024年净利润119.77亿元,同比下降15.1%

36氪获悉,海康威视披露2024年年报,报告期内,公司实现营业收入924.96亿元,同比增长3.53%;归属于上市公司股东的净利润119.77亿元,同比下降15.1%;基本每股收益1.297元。公司拟每10股派发现金红利7元(含税)。

2小时前

思特威:一季度净利润1.91亿元,同比增长1264.97%

36氪获悉,思特威披露一季报,报告期内实现营业收入17.5亿元,同比增长108.94%;归属于上市公司股东的净利润1.91亿元,同比增长1264.97%;基本每股收益0.48元。

2小时前

寒武纪:一季度净利润3.55亿元,同比扭亏

36氪获悉,寒武纪披露一季报,报告期内实现营业收入11.11亿元,同比增长4230.22%;归属于上市公司股东的净利润为3.55亿元,上年同期为亏损2.27亿元,实现扭亏为盈。

2小时前

本页详细列出关于恒瑞医药的品牌信息,含品牌所属公司介绍,恒瑞医药所处行业的品牌地位及优势。
咨询